Jade Biosciences Surges on Promising Phase 1 Data for Kidney Disease Drug
Jade Biosciences (NASDAQ: JBIO) kicked off the week with a bang, reporting positive interim results Monday from its Phase 1 trial of JADE101, an experimental treatment for immunoglobulin A nephropathy (IgAN). Investors responded quickly, pushing shares up more than 10% in pre-market trading after the stock closed Friday at $21.04.
The trial is testing single ascending subcutaneous doses of JADE101 in healthy volunteers, with researchers tracking safety, tolerability, and how the drug behaves in the body. The results delivered. A single dose drove roughly 70% reductions in immunoglobulin A (IgA) levels — and crucially, those reductions held for 12 weeks. At steady state, one subcutaneous injection every 12 weeks kept IgA suppressed at more than 70%.
Beyond the numbers, what stands out is how JADE101 compares to existing therapies. The drug produced faster, deeper, and more durable IgA lowering than first-generation anti-APRIL or dual APRIL/BAFF treatments — a meaningful distinction in a space where durability has been a persistent challenge. JADE101 also showed a clean safety profile, with patients tolerating all dose levels well.
Looking ahead, Jade expects interim data from its ongoing Phase 2 IgAN trial in 2027, with a Phase 3 registrational trial set to launch in the first half of that year. If the momentum continues, JADE101 could emerge as a serious contender in the IgAN treatment landscape.
